Kymera Therapeutics, Inc. (KYMR) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 9.09B USD. 52-week range 55.26 to 130.05 USD. Data as of 2026-10-09.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune ...